Washington, D.C. 20549

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For the month of November 2004

Commission File Number 000-28966

Biacore International AB (publ)

C/o Biacore International SA
Puits-Godet 12
CH-2000 Neuchatel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F.

Form 20-F  X
Form 40-F

Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act 
of 1934.

No   X

If "Yes" is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): Not applicable.


Uppsala, Sweden, November 16, 2004.

Biacore International AB (Biacore) announces today that, with regret, it has
accepted the resignation of Paul James, Senior Vice President of Commercial
Operations. Paul's unexpected decision to resign from Biacore is due to personal
family reasons.

Biacore has initiated the search for a new Senior Vice President of Commercial
Operations, a position that combines global responsibility for sales, product
management and marketing. The Company anticipates appointing an experienced
individual with strong commercial knowledge of the global life science sector to
this position in the early part of 2005. Until a new appointment is made Erik
Wallden, Biacore's President and CEO will assume direct responsibility of all of
the Company's commercial operations.

Erik Wallden, Biacore's President and CEO said: "I would like to thank Paul for
his contribution to Biacore, particularly the important role he played in the
recent Strategic Business Review and his rebuilding of our sales capability in
Europe. Looking ahead, I believe that the recent changes that we have made to
the Company's strategy, management and operational structure have put us in an
excellent position to move forward. I am confident that with the strong team
that we already have in place, allied to the planned recruitment of a new senior
commercial professional, we will achieve our goals of returning to profitability
in 2005."

About Biacore

Biacore is a global supplier of analytical systems that improve the productivity
of research and development in the life science and pharmaceutical markets. The
company's instruments generate unique data on protein interactions, an area of
increasing focus in these markets. The data give insights into protein
functionality, the role of proteins in normal and diseased states, and the
influence of potential drug candidates.

Use of Biacore products is well documented in key areas such as antibody
characterization, proteomics, lead optimization and bio-therapeutic development
and production. Customers include world-renowned life science research centers,
all of the leading global pharmaceutical companies and a large number of
companies in the emerging biotechnology sector. Biacore is successfully
expanding into the food analysis market, providing key manufacturers with
ready-to-use solutions for the determination of food quality and safety.

The company offers a range of products to meet specific customer needs. All
instruments utilize Surface Plasmon Resonance (SPR) technology as the basis for
detection and monitoring of protein interactions.

Biacore has its own direct sales capability in the world's key markets, United
States, Europe, Japan, Australia and a distribution network in Asia-Pacific. The
company was created in 1984, is based in Uppsala, Sweden, and is listed on the
Stockholm Stock Exchange (SSE:BCOR).

Further information on Biacore can be found on the web:


Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

Dated: December 8, 2004
Biacore International AB (publ)
By: Lars-Olov Forslund
Name: Lars-Olov Forslund
Title: Chief Financial Officer